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B E L L W E T H E R  5 0 9
by Steven Bradt
Serious infections can retard and evenhalt the growth of tumors in mammalsby blocking the formation of blood ves-
sels that nourish those tumors, researchers at
the School have found. The finding, reported
in the Cutting Edge section of the May 15 issue
of the Journal of Immunology, offers researchers
an important new lead on ways to block angio-
genesis, the growth of new small arteries and
veins.
“This finding suggests that infected animals
could be a source of new, extremely potent
inhibitors of angiogenesis, the Holy Grail of
modern anti-cancer research,” said lead author
Andrei Thomas-Tikhonenko, an assistant pro-
fessor of pathology at the School.
The result also turns on its head decades of
dogma among immunologists, who had
believed that when the cells of the immune sys-
tem were mobilized against life-threatening
infections, tumors also fell victim to this fortifi-
cation of the body’s defenses. Now, Thomas-
Tikhonenko’s work has shown that during
infection tumors don’t grow even in animals
with severely weakened immune systems. This
indicates that it’s the suppression of angio-
genesis, not antigen-battling lymphocytes and
macrophages, that holds the key to this long-
recognized phenomenon.
“This is a whole new way of looking at how
cancer can be inhibited in mammals,” said John
Hibbs, professor of internal medicine and chief
of the Infectious Disease Division at the Uni-
versity of Utah, who has conducted research on
infection-mediated suppression of tumorigene-
sis. “For a number of years, immunologists
have regarded this process as a cytotoxic effect
mediated by lymphocytes and activated
macrophages. This work shows that infections
also inhibit tumors by a surprisingly different
mechanism.”
Thomas-Tikhonenko’s research, which has
not fingered a specific factor that blocks angio-
genesis in infected animals, creates a kind of
scientific whodunit. The Penn team is search-
ing for the mystery molecules, pressed into
service by infections, that so strongly inhibit
the growth of vascular tissues inside the
tumors.
“We are very much interested in identifica-
tion of these ‘culprits’ because we believe that
they will be extremely useful therapeutic agents
not only for cancer but also for other diseases
where unwanted angiogenesis takes place,”
Thomas-Tikhonenko said. Angiogenesis is
known to play a role in diabetic retinopathy, a
leading cause of blindness, and endometriosis,
a major contributor to female infertility.
The first observation that infection inter-
feres with tumor growth was made more than
100 years ago by a New York surgeon, William
B. Coley, who noted that streptococcal infec-
tion caused regression of soft tissue sarcomas
in human patients. Traditionally, this resistance
has been explained by stimulation of anti-
tumor immunity.
“However, direct proof of this mechanism
has never been obtained, and therapies based
on it have not materialized,” Thomas-
Tikhonenko said. “In our paper, we demon-
strate, for the first time, that infection-induced
resistance need not involve any of the immune
responses that might limit tumor growth.”
Two separate lines of evidence suggested to
the Penn researchers that the immune system
doesn’t play a crucial role in inhibiting tumors.
First, in strains of mice lacking the cells nor-
mally found on the front lines of the immune
system — T-lymphocytes, macrophages and
NK cells — tumor growth was nevertheless
suppressed when the protozoan Toxoplasma
gondii was contracted. Further support came
from the earlier observation that the tumor
under investigation, the B16 variant of malig-
nant melanoma, produced no antigens recog-
nizable to the mouse’s immune system.
After he had ruled out the immune system
as intermediary between infection and tumori-
genesis, Thomas-Tikhonenko was tipped off to
angiogenesis’ role by co-author and toxoplas-
mosis expert Christopher Hunter, associate
professor of parasitology at the School. Hunter
suggested that the same mouse proteins
designed to guard the host against Toxoplasma
gondii might also inhibit growth of blood ves-
sels. This suggestion proved correct: in a pilot
experiment, the injection of powerful angio-
genic compounds into mice with toxoplasmo-
sis failed to induce growth of new blood vessels
under the skin, a phenomenon that has impor-
tant implications for cancer.
The tiniest of tumors don’t require their
own blood vessels, relying on simple diffusion
of oxygen and nutrients from nearby cells. But
by the time they’ve grown to two or three mil-
limeters in size, tumors need the nourishment
provided by blood vessels in order to survive.
The laboratories of Thomas-Tikhonenko and
William Lee at Penn’s School of Medicine
found that at this stage, where angiogenesis
becomes crucial, melanomas developing in
infected mice experience severe lack of oxygen
but are unable to recruit new endothelial cells
to produce blood vessels.
Thomas-Tikhonenko’s findings suggest that
Toxoplasma gondii-infected animals could be
used to purify molecules that halt the suste-
nance of tumors. Although several anti-
angiogenic compounds have been recently
identified, their efficacies are yet to be proven
in clinical trials and none of them has been
approved by the Food and Drug Administra-
tion for the treatment of cancer patients.
The drive to pinpoint the exact chemical
factor that prompts infections to block angio-
genesis will likely take months, possibly years.
“It might be a combination of well-known
molecules such as interferons or an entirely
new compound,” Hunter said.
Thomas-Tikhonenko and Hunter’s co-
authors on the Journal of Immunology paper
are Duonan Yu, Cam Ngo, Cinzia Sevignani,
Michael Goldschmidt and Sidney Evans of
Penn’s School of Veterinary Medicine; Michael
Gee and William Lee of Penn’s School of Medi-
cine; and Tatyana Golovkina of the Jackson
Laboratory in Bar Harbor, Me. Their work was
funded by the National Institute of Allergy and
Infectious Diseases, the National Cancer Insti-
tute and the University of Pennsylvania Cancer
Center Pilot Projects Program.
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New Faculty Member
Dr. Ilana Reisner has been appointed
assistant professor of behavioral medicine
and director of VHUP’s behavior clinic. Dr.
Reisner came to Penn from Cornell Univer-
sity’s College of Veterinary Medicine where
she was a visiting fellow. She received her
D.V.M. degree from the Veterinary College
at Oregon State University and then went to
Cornell for a Ph.D. in behavioral physiology
with an interest in canine aggression.
During part of her residency in behavioral
medicine at Cornell, Dr. Reisner was a
Morris Animal Foundation Fellow. Dr.
Reisner became a diplomate of the Ameri-
can College of Veterinary Behaviorists in
1995.
